美國FDA顧問支持Ardelyx腎臟疾病藥物Tenapanor
格隆匯11月17日丨美國FDA週三建議批准Ardelyx(ARDX.US)的Tenapanor用於慢性腎病透析患者的藥物,該藥物最初被拒絕一年多。Tenapanor是一種口服藥物,通過靶向吸收途徑來降低體內磷酸鹽的水平。目前,磷酸結合劑是唯一被批准的治療高磷血癥的方法。高磷血癥是一種導致血液中磷含量異常高的疾病,是腎臟損傷的跡象。根據去年的一份政府報吿,美國約有3700萬人,即七分之一的人患有慢性腎臟疾病。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.